Dermatology Enrollment Form: Humira

FACTOR ONE SOURCE FAST PHARMACY
Powered By: InfuCare Rx

Phone: 1-833-FOS-FAST
Fax: 844-533-1131
Website: www.FOSRXFAST.com
Louisiana Office
3131 N. 1-10 Service Rd. E., Ste. 202
Metairie, LA 70002

PATIENT INFORMATION

Name:
Address:
City: State/Zip:
Telephone: DOB: _____ M ☐ F ☐
Language Preference: Wt: Ht:

PRESCRIBER INFORMATION

Prescribing Practioner: NPI:
Address:
City State/Zip
Office: DEA:
Contact: Phone: Fax:

PRIMARY INSURANCE INFORMATION

Member Name: M ☐ F ☐ DOB: _____
Address: City:
State: Zip: Telephone: Alt. Telephone:
Member ID: Rx Group #: BIN#:
PCN#: Customer Service #:

PRESCRIPTION

New ☐ Refill ☐ Ship by: _____ Ship to: ☐ Patient's Home ☐ Doctor's Office ☐ Other:_____

Drug		Directions	Refills
Humira® Citrate Free	☐ Psoriasis Starter Kit ☐ Pen ☐ Pre-filled Syringe	☐ **INITIAL:** Inject 80 mg SQ on Day 1, 40 mg on Day 8, then 40 mg every **other** week (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every **other** week (Quantity: 2)	
	☐ HS Starter Kit ☐ Pen ☐ Pre-filled Syringe	**ADULT:** ☐ **INITIAL:** Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every week (Quantity: 4)	
	☐ Adolescent HS Starter Kit ☐ Pen ☐ Pre-filled Syringe	**ADOLESCENT: **WEIGHT REQUIRED***** _____ ☐ **INITIAL:** Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every week (Quantity: 4) ****Intended for weight > 60 kg/132 lbs***** _____	
		ADOLESCENT: **WEIGHT REQUIRED*** _____ ☐ **INITIAL:** Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every week (Quantity: 4) ****Intended for weight > 60 kg/132 lbs***** _____	
Humira®	☐ Psoriasis Starter Kit ☐ Pen ☐ Pre-filled Syringe	☐ **INITIAL:** Inject 80 mg SQ on Day 1, 40 mg on Day 8, then 40 mg every **other** week (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every **other** week (Quantity: 2)	
	☐ HS Starter Kit ☐ Pen ☐ Pre-filled Syringe	**ADULT:** ☐ **INITIAL:** Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every week (Quantity: 4)	
	☐ Adolescent HS Starter Kit ☐ Pen ☐ Pre-filled Syringe	**ADOLESCENT: **WEIGHT REQUIRED***** _____ ☐ **INITIAL:** Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every week (Quantity: 4) ****Intended for weight > 60 kg/132 lbs***** _____	
		ADOLESCENT: **WEIGHT REQUIRED*** _____ ☐ **INITIAL:** Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) ☐ **MAINTENANCE:** Inject 40 mg SQ every week (Quantity: 4) ****Intended for weight > 60 kg/132 lbs***** _____	

MEDICAL INFORMATION ***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY ***

Previous Therapies:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
☐ Methotrexate	☐ (_____)	☐	_____
☐ Soriatane	☐ (_____)	☐	_____
☐ Clobetasol	☐ (_____)	☐	_____
☐ Hydrocortisone	☐ (_____)	☐	_____
☐ Eucrisa	☐ (_____)	☐	_____
☐ Stelara	☐ (_____)	☐	_____
☐ Enbrel	☐ (_____)	☐	_____
☐ _____	☐ (_____)	☐	_____
☐ _____	☐ (_____)	☐	_____

☐ Face
☐ Feet
☐ Groin
☐ Hands
☐ Nails
☐ Scalp
☐ Other: _____



Scoring Tool Used
☐ BSI ☐ EASI ☐ SCORAD
☐ POEM ☐ ISGA ☐ % or SCORE _____

PHOTOTHERAPY	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
☐ UVA/UVB	☐ (_____)	☐	_____

☐ Patient Cannot Afford ☐ Photosensitivity ☐ Risk of skin cancer ☐ Distance from office

Date of Diagnosis: _____
Allergies: _____

Active TB is ruled out: ☐
Date: _____
Hep B ruled out/treated: ☐
Date: _____

☐ L40.Psoriasis Vulgaris (Plaque Psoriasis)
☐ L73.2 Hidradenitis suppurativa
☐ L40.____ _____
☐ Other: _____

INJECTION TRAINING: ☐ Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ FOSRX/FAST to coordinate injection training

AMERICAN ACADEMY OF DERMATOLOGY CONSENSUS STATEMENT ON PSORIASIS THERAPIES

☐ Psoriasis is covering greater than 10% body surface area
☐ Psoriasis is on palms, soles, head & neck, or genitals
☐ Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
☐ Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment, or interpersonal relationships

PRESCRIBING PRACTITIONER SIGNATURE

To Prescribing Practitioner: By signing this form and utilizing our services, you are also authorizing FOSRX/FAST to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies and co-pay foundations.

Prescribing Practitioner: **Date:**